Chemical compounds Press Release
|06/22/2020 - 18:06||
Preliminary Injunction Sought to Release Hydroxychloroquine to the Public
Today the Association of American Physicians & Surgeons filed its motion for a preliminary injunction to compel release to the public of hydroxychloroquine by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. HHS , No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.). Nearly 100 million doses of hydroxychloroquine (HCQ) were donated to these agencies, and yet they have not released virtually any of it to the public.
|06/15/2020 - 17:30||
Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine
Today, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible.
|06/15/2020 - 00:53||
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use
Today, the U.S. Food and Drug Administration is warning health care providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.
|06/12/2020 - 18:45||
Sorrento Announces Full Repayment of Outstanding Term Loans
The prepaid debt, comprised of an initial $100 million term loan and an additional $20 million term loan from certain funds affiliated with Oaktree Capital Management, L.P. , was obtained pursuant to a Term Loan Agreement entered into in November 2018 .
|06/12/2020 - 09:47||
FDA Approves Drug to Treat Infants and Children with HIV
Today, the U.S. Food and Drug Administration approved Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg (6.61 pounds) in combination with other antiretroviral treatments.
|06/10/2020 - 19:33||
Alaska Attorney General Joins Coalition Filing 3rd Complaint in Ongoing Antitrust Price-Fixing Investigation into Generic Drug Industry
Complaint Names 26 Corporate Defendants, 10 Individual Defendants in Conspiracy to Fix Prices and Allocate Markets for at least 80 Generic Topical Dermatological Drugs.
|06/10/2020 - 10:13||
Governor Cuomo Announces Insurance Fraud Action Against Global Opioid Manufacturer
Governor Andrew M. Cuomo today announced the New York State Department of Financial Services has filed charges and initiated administrative proceedings against Endo International plc and its subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., and Par Pharmaceutical Companies, Inc. These charges are the second to be filed in DFS' ongoing investigation into the entities that created and perpetuated the opioid crisis.
|New York Governor|
|06/09/2020 - 12:29||
Delaware growers allowed to use up existing dicamba stock
DOVER, Del. (June 9, 2020) – Following the Ninth Circuit Court of Appeals’ decision to vacate three dicamba registrations, the United States Environmental Protection Agency (EPA) has issued guidance that will allow Delaware growers to used existing stocks of the three dicamba products affected.
|Delaware State ...|
|06/03/2020 - 17:18||
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
William Blair 40 th Annual Growth Stock Conference : Exelixis is scheduled to present at 11:40 AM EDT / 8:40 AM PDT on Tuesday, June 9, 2020 . Goldman Sachs 41st Annual Global Healthcare Conference: Exelixis is scheduled to present at 2:10 PM EDT / 11:10 AM PDT on Wednesday, June 10, 2020 . BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference : Exelixis is scheduled to present at 4:00 PM EDT / 1:00 PM PDT on Tuesday, June 23, 2020 .
|06/02/2020 - 08:22||
COVID-19 Drug Development Could Benefit from Approach Used Against Flu
AUSTIN, Texas — A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better — they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.
|University of Texas|
|06/01/2020 - 11:26||
Buy Diazepam at Cost-Effective Prices for the Treatment of Several Different Disorders - Sleeping Pills UK
Diazepam 10mg tablets can now be purchased online. Reliable online pharmacies aim to provide patients with a simple solution to help them with their disorder. With efficient systems in place, these reliable online pharmacies can now offer doorstep delivery of medication. One can now order medication at affordable prices from their computers with just a few clicks of a mouse - Sleeping Pills UK
|06/01/2020 - 08:16||
TelBari - Organic Herbal Skincare Uses Frequency Energized Water in its Formulations
Frequency is the language that all life understands at a cellular level. It is the foundation upon which every physiological process is based.
|05/18/2020 - 16:21||
COVID-19 Caused Hydroxychloroquine Issues for Third of Lupus Patients, New LRA Survey Finds
NEW YORK, NY, May 28. More than one third of people with lupus experienced significant issues filling their hydroxychloroquine (Plaquenil) prescriptions during the COVID-19 pandemic, according to results of a new survey conducted by the Lupus Research Alliance (LRA). Hydroxychloroquine shortages in March and April coincided with early data broadly reported in the media suggesting possible benefit for hydroxychloroquine to treat or prevent COVID-19.
|05/18/2020 - 14:13||
Real-world Data Used to Help Predict Demand for Drug Inventory During Pandemic
The arrival of COVID-19 in the United States and its ensuing spread, as well as evolving developments on the disease, have meant that healthcare professionals have had to rapidly adapt in order to care for the growing patient population. In New York, the U.S. epicenter of the pandemic, real-world data (RWD) has been used to help predict demand for drug inventory for the treatment of COVID-19.
|05/18/2020 - 09:12||
New remdesivir trial at UIC tests drug in combination with baricitinib
The University of Illinois at Chicago is enrolling patients in a second clinical trial to study the drug remdesivir as a treatment for COVID-19.
|05/18/2020 - 01:43||
Global HIV prevention study to stop early after ViiV Healthcares long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition Participants who were in the daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (FTC/TDF) tablet arm of the study will be offered CAB LA
|05/17/2020 - 17:23||
RUBRACA: INNOVATIVE DRUG SHOWS HOPE FOR ADVANCED PROSTATE CANCER PATIENTS
INNOVATIVE DRUG GIVES HOPE FOR ADVANCED PROSTATE CANCER PATIENTS Breakthrough Development from Clovis Oncology Offers First PARP Inhibitor Confirmed in a Prostate Cancer Setting.
|ZERO - The Proj...|
|05/15/2020 - 17:04||
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
Today, the U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. Qinlock is indicated for adult patients who have received prior treatment with three or more kinase inhibitor therapies, including imatinib.
|05/14/2020 - 08:19||
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)
First Patient Dosed with Optimized One-Hour Dosing Schedule for Investigational Agent Alvocidib After Azacitidine.
|05/13/2020 - 23:14||
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA mutation.
|05/12/2020 - 22:06||
AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program
Data to showcase unprecedented efficacy for Tagrisso in early-stage lung cancer and survival results for Imfinzi in small cell lung cancer
|05/12/2020 - 19:50||
ACP: Evidence Does Not Support Chloroquine or HCQ Use Alone or in Combination with Azithromycin as Prophylaxis for COVID-19
Philadelphia, PA (May 13, 2020) – In new Practice Points, the American College of Physicians (ACP) says that evidence does not support the use of chloroquine or hydroxychloroquine alone or in combination with azithromycin to prevent COVID-19 after infection with novel coronavirus (SARS-CoV-2), or for treatment of patients with COVID-19.
|05/12/2020 - 14:28||
15% of Postdoctoral Researcher applicants in natural sciences and engineering granted funding
The Academy of Finland’s Research Council for Natural Sciences and Engineering today decided on funding for 43 new posts as Postdoctoral Researcher. The funding totals around 11 million euros, and the success rate was around 15 per cent. Women account for some 28 per cent of the funding recipients and for 30 per cent of the applicants.
|Academy of Finland|
|05/12/2020 - 12:50||
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
JAVELIN Bladder 100 Study to be presented in Plenary Session and featured in the official Press Program.
|05/12/2020 - 09:02||
Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.